FDA Approval Alert: The Need-to-Know | Tarlatamab in Extensive-Stage Small Cell Lung Cancer

In May 2024, the FDA granted accelerated approval to tarlatamab-dlle for patients with extensive-stage small cell lung cancer who have progressed on platinum-based chemotherapy.

The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.
FDA Approves Tarlatamab After Progression on Chemotherapy in ES-SCLC
Article
May 16, 2024 8:15 PM
The phase 2 DELLphi-301 trial showed durable response rates when tarlatamab was used to treat extensive-stage small cell lung cancer.